-
Selpercatinib, sold
under the
brand name
Retevmo among others, is a
medication for the
treatment of
cancers in
people whose tumors have an alteration...
- as a RET inhibitor.
Enbezotinib Pralsetinib Rebecsinib Resigratinib Selpercatinib Vodopivec DM, Hu MI (2022). "RET
kinase inhibitors for RET-altered thyroid...
-
selective RET inhibitors.
Around 2017, the
first selective RET
inhibitors selpercatinib (LOXO-292) and
pralsetinib (BLU-667)
started their first phase I/II...
-
Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
Repifermin Selpercatinib Trafermin Velafermin FGFR2 Agonists:
Ersofermin FGF (1, 2 (bFGF), 3...
-
Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
Repifermin Selpercatinib Trafermin Velafermin FGFR2 Agonists:
Ersofermin FGF (1, 2 (bFGF), 3...
-
potential treatment for leukemia.
Enbezotinib Pralsetinib Resigratinib Selpercatinib Zeteletinib Butler MS (September 2013). "Remediating
cancer via splicing...
- been
approved for
medical use
include Pembrolizumab, Larotrectinib,
Selpercatinib, Entrectinib, and Pralsetinib.
Pembrolizumab was
approved by the US...
-
Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
Repifermin Selpercatinib Trafermin Velafermin FGFR2 Agonists:
Ersofermin FGF (1, 2 (bFGF), 3...
-
Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
Repifermin Selpercatinib Trafermin Velafermin FGFR2 Agonists:
Ersofermin FGF (1, 2 (bFGF), 3...
-
Ersofermin FGF (1, 2 (bFGF), 3, 4, 5, 6, 8, 10 (KGF2), 20)
Repifermin Selpercatinib Trafermin Velafermin FGFR2 Agonists:
Ersofermin FGF (1, 2 (bFGF), 3...
